Lotus Pharmaceutical Co., Ltd. (“Lotus” or “the Company”, Taiwan TWSE ticker: 1795) and DKSH Business Unit Healthcare today announced their strategic partnership to expand into the Philippines. This collaboration will provide DKSH the exclusive rights to market Lotus’ treatment for Parkinson’s disease, Stalevo®, in the Philippines.
Petar Vazharov, Chief Executive Officer of Lotus, commented: “As being strongly committed to making a difference for our patients, we are pleased to have DKSH as our strategic partner to ensure our Parkinson’s products are accessible to patients across APAC. The market expansion into the Philippines will not just benefit us and DKSH, but also the patients in the country who suffer from Parkinson’s disease for tremor, muscle stiffness, slowness and poor movement and control.”
Further to the cooperation with Lotus for Singapore during 2018 and 2019 with successful growth, the extension of this partnership to the Philippines, specifically for their Parkinson’s treatment, emphasizes DKSH’s capability to enrich people’s lives and increase market share thanks to an extensive network of hospitals, clinics and pharmacies across the region. This collaboration complies with DKSH’s strategic direction of strengthening its regional footprint in the Philippines.
Bijay Singh, Global Head of Business Unit Healthcare, DKSH, said: “Our vision is to enrich people’s lives. We provide the best possible commercial outsourcing service to our clients, so that they, in turn, can focus on their core competencies in developing excellent products to improve the lives of patients. We are thrilled to support Lotus in expanding their market presence to the Philippines. Through our extensive networks of hospitals, clinics and pharmacies, we will grow Lotus’ visibility and its product portfolio will help a lot of Filipino patients with Parkinson’s disease.”